Covid-19: New Zealand reports first death linked to Pfizer vaccine

Bloomberg August 30 | Updated on August 30, 2021

The country is currently in a national lockdown due to a community outbreak of the delta strain

New Zealand health authorities reported what they believe to be the country’s first death linked to the Pfizer Covid-19 vaccine.

A woman died from myocarditis, an inflammation of the heart muscle wall, following her Pfizer vaccination, New Zealand’s Covid-19 Vaccine Independent Safety Monitoring Board said in an emailed statement on Monday. It said myocarditis is known to be a rare side effect of the Pfizer vaccine.

Ramping up vaccination

The case has been referred to the coroner and the cause of death has not yet been determined, however the board “considered that the myocarditis was probably due to vaccination,” it said. “This is the first case in New Zealand where a death in the days following vaccination has been linked to the Pfizer Covid-19 vaccine.”

India, New Zealand discuss access to Covid-19 vaccines

New Zealand is currently in a national lockdown due to a community outbreak of the highly infectious delta strain of Covid-19. It is ramping up what has been one of the slowest vaccine roll-outs in the developed world, and is only using Pfizer. More than 3.3 million doses of the two-dose vaccine have so far been administered, enough to fully immunise about 23 per cent of the population.

Delta variant not different among vaccinated and unvaccinated in Chennai: ICMR

“The benefits of vaccination with the Pfizer Covid-19 vaccine continue to greatly outweigh the risk of both Covid-19 infection and vaccine side effects, including myocarditis,” the board said. “The Pfizer vaccine is highly effective in protecting against serious illness and death from Covid-19, and we remain confident about using it in New Zealand.”

Published on August 30, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like